Want to see HK:0239 full AI Analyst Report?
0239 Stock Chart & Stats
HK$2.38
-HK$0.03(-1.22%)
At close: 4:00 PM EST
HK$2.38
-HK$0.03(-1.22%)
Day’s Range― - ―
52-Week RangeHK$2.24 - HK$2.73
Previous CloseN/A
Volume52.50K
Average Volume (3M)53.37K
Market Cap
HK$765.08M
Enterprise ValueHK$348.39
Total Cash (Recent Filing)HK$400.27M
Total Debt (Recent Filing)HK$6.95M
Price to Earnings (P/E)7.8
Beta-0.14
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.54%
Share Statistics
EPS (TTM)0.32
Shares Outstanding311,640,000
10 Day Avg. Volume79,350
30 Day Avg. Volume53,366
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)1.02
Price to Sales (P/S)3.45
P/FCF Ratio6.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilitySustained high profitability across recent years indicates a resilient branded consumer-health business with strong earnings conversion. This provides internal funding capacity and can support marketing, product maintenance and distribution investment over the next several quarters.
Very Low LeverageThe conservative balance sheet limits interest and refinancing risk while preserving flexibility. Low leverage should help the company withstand demand fluctuations, meet regulatory or operating needs, and sustain shareholder distributions without excessive financial strain.
Robust Recent Cash GenerationStrong recent operating and free cash flow, generally tracking net income, supports the quality of reported earnings. Reliable internal cash generation can fund inventory, distribution and brand investment while reducing dependence on external financing.
Bears Say
Revenue VolatilityUneven top-line performance makes the earnings base less predictable and may reflect sensitivity to product demand, geographic mix or distribution volumes. Persistent revenue volatility could limit operating leverage and make future margin strength harder to sustain.
Inconsistent Historical ReturnsThe contrast between strong recent returns and weak earlier periods shows that profitability is not fully consistent through the cycle. This history suggests the brand and business model remain exposed to changing demand or operating conditions despite the current balance-sheet strength.
Volatile Cash FlowAlthough recent cash generation is strong, historical swings and the decline in 2024 reduce confidence that cash conversion will remain smooth. Missing or zero latest-period coverage fields also limit confirmation of liquidity and payout sustainability.
Pak Fah Yeow International Limited News
0239 FAQ
What was Pak Fah Yeow International Limited’s price range in the past 12 months?
Pak Fah Yeow International Limited lowest stock price was HK$2.24 and its highest was HK$2.73 in the past 12 months.
What is Pak Fah Yeow International Limited’s market cap?
Pak Fah Yeow International Limited’s market cap is HK$765.08M.
When is Pak Fah Yeow International Limited’s upcoming earnings report date?
Pak Fah Yeow International Limited’s upcoming earnings report date is Apr 01, 2027 which is in 195 days.
How were Pak Fah Yeow International Limited’s earnings last quarter?
Pak Fah Yeow International Limited released its earnings results on Aug 20, 2026. The company reported HK$0.152 earnings per share for the quarter.
Is Pak Fah Yeow International Limited overvalued?
According to Wall Street analysts Pak Fah Yeow International Limited’s price is currently Overvalued.
Does Pak Fah Yeow International Limited pay dividends?
Pak Fah Yeow International Limited pays a Notavailable dividend of HK$0.09 which represents an annual dividend yield of 7.54%. See more information on Pak Fah Yeow International Limited dividends here
What is Pak Fah Yeow International Limited’s EPS estimate?
Pak Fah Yeow International Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pak Fah Yeow International Limited have?
Pak Fah Yeow International Limited has 311,640,000 shares outstanding.
What happened to Pak Fah Yeow International Limited’s price movement after its last earnings report?
Pak Fah Yeow International Limited reported an EPS of HK$0.152 in its last earnings report. Following the earnings report the stock price went up 2.049%.
Which hedge fund is a major shareholder of Pak Fah Yeow International Limited?
Currently, no hedge funds are holding shares in HK:0239
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pak Fah Yeow International Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.26%
12-Months-Change
Fundamentals
Return on Equity
7.54%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pak Fah Yeow International Limited
Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and other international territories. The company's operations are categorized into three distinct divisions: Healthcare, Property Investments, and Treasury Investments. Among its key offerings are medicated oils, such as white flower embrocation, along with various ointments and solutions for strain relief, including the floral-scented Fúzai 239 white flower embrocation. Beyond its primary healthcare focus, the firm also commits capital to diverse real estate assets, encompassing commercial, industrial, residential, and car park properties, and additionally provides advertising agency services. This enterprise, established in 1927, maintains its corporate headquarters in Wan Chai, Hong Kong.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
JBM (Healthcare) Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―